The stimulant properties of AFA were discovered serendipitously at [[Sterling Drug|Sterling-Winthrop]] in the midst of research on the antibiotic [[nalidixic acid]].<ref name="Hamilton"/> In addition to behaving as antibiotics, it was found that many derivatives of nalidixic acid have either stimulant or depressant effects on the [[central nervous system]].<ref>{{ cite patent | country = US | status = patent | number = 3590036 | title = Naphthyridine-3-carboxylic Acids, Their Derivatives and Preparation Thereof }}</ref> Researchers at Sterling-Winthrop found that AFA had a higher potency and [[therapeutic index]] than [[cocaine]] or [[amphetamine]] and so it was singled out for further study.<ref name="Hamilton"/><ref>{{Cite journal|pmid=4393073|year=1970|last1=Aceto|first1=M.A.|title=Pharmacologic properties and mechanism of action of amfonelic acid|pages=344–354|journal=European Journal of Pharmacology|doi=10.1016/0014-2999(70)90206-2|volume=10}}</ref> A small number of clinical trials were held in the 1970s, but when it was found that AFA exacerbated psychotic symptoms in schizophrenic patients and produced undesirable stimulant properties in geriatric depressives clinical evaluation of AFA was discontinued.<ref name="Hamilton"/> AFA remains a widely used pharmacological tool for study of the brain's [[reward system]], [[dopamine pathways]], and the [[dopamine transporter]].<ref name=Hamilton /> Since 2013 AFA has been sold on the [[gray market]] and there are numerous anecdotal reports detailing its [[Recreational drug use|non-medical use]].<ref name=Hamilton />

 
In studies it proved to be a potent and highly selective [[dopamine reuptake inhibitor]] (DRI) in rat brain preparations.<ref name="pmid24701">{{ cite journal |author1=Fuller, R. W. |author2=Perry, K. W. |author3=Bymaster, F. P. |author4=Wong, D. T. | title = Comparative effects of pemoline, amfonelic acid and amphetamine on dopamine uptake and release in vitro and on brain 3,4-dihydroxyphenylacetic acid concentration in spiperone-treated rats. | journal = Journal of Pharmacy and Pharmacology | volume = 30 | issue = 3 | pages = 197–198 | year = 1978 | pmid = 24701 | doi = 10.1111/j.2042-7158.1978.tb13201.x }}</ref><ref name="pmid27622">{{ cite journal |author1=McMillen, B. A. |author2=Shore, P. A. | title = Amfonelic acid, a non-amphetamine stimulant, has marked effects on brain dopamine metabolism but not noradrenaline metabolism: Association with differences in neuronal storage systems | journal = Journal of Pharmacy and Pharmacology | year = 1978 | volume = 30 | issue = 7 | pages = 464–466 | pmid = 27622 | doi = 10.1111/j.2042-7158.1978.tb13293.x }}</ref> A study found a moderately long [[half-life]] of approximately 12 hours and a dopaminergic potency approximately 50 fold that of [[methylphenidate]] in rat brain preparations.<ref name="pmid2145054">{{ cite journal |author1=Izenwasser, S. |author2=Werling, L. L. |author3=Cox, B. M. | title = Comparison of the effects of cocaine and other inhibitors of dopamine uptake in rat striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal cortex | journal = Brain Research | volume = 520 | issue = 1–2 | pages = 303–309 | year = 1990 | pmid = 2145054 | doi=10.1016/0006-8993(90)91719-W}}</ref> Despite lack of direct serotonin activity, rats treated with subchronic doses of amfonelic acid display subsequent decreases in [[5HT]] and [[5HIAA]].<ref>{{Cite journal|pmid=2018630|year=1991|last1=McMillen|first1=BA|last2=Scott|first2=SM|last3=Williams|first3=HL|title=Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotonergic function|volume=83|issue=1–2|pages=55–66|journal=Journal of neural transmission. General section|doi=10.1007/BF01244452}}</ref> Amfonelic acid displays no activity in the [[norepinephrine]] system.<ref>{{Cite journal|pmid=9085190|year=1997|last1=Agmo|first1=A|last2=Belzung|first2=C|last3=Rodríguez|first3=C|title=A rat model of distractibility: Effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission|volume=104|issue=1|pages=11–29|journal=Journal of neural transmission (Vienna, Austria : 1996)|doi=10.1007/BF01271291}}</ref>

 
Despite its different mechanism of action, amfonelic acid displays [[discriminatory substitution]] with 150% the stimulant potency of [[dextroamphetamine]].<ref>{{Cite journal|pmid=6728880|year=1984|last1=Aceto|first1=MD|last2=Rosecrans|first2=JA|last3=Young|first3=R|last4=Glennon|first4=RA|title=Similarity between (+)-amphetamine and amfonelic acid|volume=20|issue=4|pages=635–7|journal=Pharmacology, Biochemistry, and Behavior|doi=10.1016/0091-3057(84)90316-2}}</ref> Amfonelic acid has been shown to be neuroprotective against [[methamphetamine]] damage to dopamine neurons.<ref>{{Cite journal|pmid=7953636|year=1994|last1=Pu|first1=C|last2=Fisher|first2=JE|last3=Cappon|first3=GD|last4=Vorhees|first4=CV|title=The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum|volume=649|issue=1–2|pages=217–24|journal=Brain Research|doi=10.1016/0006-8993(94)91067-7}}</ref> It also increases the effects of the antipsychotic drugs [[haloperidol]], [[trifluoperazine]] and [[spiperone]].<ref>{{Cite journal|pmid=2857083|year=1985|last1=Waldmeier|first1=PC|last2=Huber|first2=H|last3=Heinrich|first3=M|last4=Stoecklin|first4=K|title=Discrimination of neuroleptics by means of their interaction with amfonelic acid: An attempt to characterize the test|volume=34|issue=1|pages=39–44|journal=Biochemical Pharmacology|doi=10.1016/0006-2952(85)90097-8}}</ref> Rats are shown to self-administer amfonelic acid in a dose-dependent manner.<ref>{{Cite journal|pmid=2908003|year=1988|last1=Porrino|first1=LJ|last2=Goodman|first2=NL|last3=Sharpe|first3=LG|title=Intravenous self-administration of the indirect dopaminergic agonist amfonelic acid by rats|volume=31|issue=3|pages=623–6|journal=Pharmacology, Biochemistry, and Behavior|doi=10.1016/0091-3057(88)90240-7}}</ref>
